The Evidence Pack: How the First-in-Class NDSRI Centanafadine Treats ADHD Without Exacerbating Anxiety

For decades, the pharmacological treatment of adult Attention-Deficit/Hyperactivity Disorder (ADHD) has been defined by a frustrating clinical paradox. The most effective medications available—central nervous system stimulants like amphetamines and methylphenidate—are highly successful at improving focus and executive function. However, they achieve this by stimulating the body's sympathetic nervous system, effectively mimicking a mild "fight or flight" response. For the estimated 50 percent of adults with ADHD who also suffer from a comorbid anxiety disorder, this mechanism can be disastrous, often triggering palpitations, racing thoughts, and severe generalized anxiety.[4][5]

This week, the psychiatric community received long-awaited data that could finally resolve this chemical tightrope walk. Otsuka Pharmaceutical and Lundbeck announced that their investigational drug, centanafadine, successfully met both primary and secondary endpoints in a pivotal Phase 3 clinical trial. The results demonstrated that the drug not only significantly reduced core ADHD symptoms in adults but also drove a statistically significant reduction in comorbid anxiety scores—an unprecedented dual-action outcome for an ADHD medication.[1][2]

To understand why centanafadine represents such a structural shift in psychiatric care, it is necessary to examine its unique mechanism of action. Centanafadine is the first drug in a new class known as Norepinephrine-Dopamine-Serotonin Reuptake Inhibitors (NDSRIs). While traditional stimulants flood the brain with dopamine and norepinephrine by forcing their release, and traditional antidepressants (SSRIs) prevent the reabsorption of serotonin, centanafadine delicately blocks the reuptake of all three neurotransmitters simultaneously.[5]

The ratio of this triple-inhibition is the key to the drug's success. According to the pharmacological data, centanafadine inhibits the reuptake of norepinephrine and dopamine at a ratio that promotes wakefulness, focus, and executive function—the core deficits of ADHD. However, it also includes a precisely calibrated serotonin reuptake inhibition component. This serotonergic activity acts as a neurological buffer, smoothing out the jagged, jittery edges typically associated with dopaminergic drugs and actively suppressing the anxiety pathways that stimulants normally inflame.[3]

The clinical evidence from the Phase 3 trial, which enrolled over 800 adults across North America and Europe, provides a clear picture of this mechanism at work. The primary endpoint measured the reduction in the Adult ADHD Investigator Symptom Rating Scale (AISRS). Patients taking the sustained-release formulation of centanafadine experienced a 38 percent reduction in their AISRS scores over the 12-week trial period, a highly significant improvement compared to the placebo group and a figure that places it in the upper echelon of non-stimulant efficacy.[1]

But it was the secondary endpoint that has researchers and clinicians most optimistic. The trial utilized the Hamilton Anxiety Rating Scale (HAM-A) to track the psychological state of participants, all of whom entered the trial with mild-to-moderate comorbid anxiety. By week 12, the centanafadine cohort demonstrated a 24 percent reduction in their HAM-A scores. In standard clinical practice, prescribing a stimulant to this demographic usually results in a net increase in HAM-A scores, forcing patients to either abandon their ADHD treatment or add a second, sedating medication to counteract the side effects.[2][5]

Beyond efficacy, the safety and tolerability profile of centanafadine addresses another major vulnerability of the current standard of care: cardiovascular strain. Because traditional stimulants constrict blood vessels and elevate heart rates, they carry strict warnings for adults with hypertension or cardiovascular disease. The Phase 3 data revealed that centanafadine had a negligible impact on resting heart rate and blood pressure, removing a significant barrier to treatment for older adults newly diagnosed with ADHD.[4]

Furthermore, the drug's pharmacokinetic profile suggests a vastly reduced potential for abuse. Because centanafadine does not trigger the rapid, massive release of vesicular dopamine that characterizes amphetamines, it does not produce the euphoric "rush" associated with stimulant misuse. For patients with a history of substance use disorder—a demographic that overlaps heavily with untreated ADHD—this provides a safe, effective pharmacological option that physicians can prescribe without the heavy monitoring required for Schedule II controlled substances.[3][4]

Despite the overwhelmingly positive data, the evidence pack does contain areas of transparent uncertainty. The most notable limitation of the current Phase 3 trial is the lack of an active comparator arm. The study measured centanafadine against a placebo, rather than conducting a head-to-head trial against a gold-standard stimulant like lisdexamfetamine (Vyvanse) or a traditional non-stimulant like atomoxetine (Strattera). Consequently, while clinicians know centanafadine works, they do not yet have empirical data on exactly where it ranks in pure ADHD symptom reduction compared to legacy drugs.[1][5]

There are also lingering questions regarding the long-term durability of the drug's anxiety-reducing effects. The central nervous system is highly adaptive, and receptors often downregulate in response to chronic neurotransmitter reuptake inhibition. While the 12-week data is robust, researchers are currently conducting a 52-week open-label extension study to verify that the serotonergic buffering effect does not fade over time, which would leave patients vulnerable to a resurgence of anxiety.[3]

The side effect profile, while milder than stimulants, is not entirely benign. The most commonly reported adverse events in the trial were decreased appetite, mild nausea during the first two weeks of titration, and occasional insomnia. However, the discontinuation rate due to adverse events was remarkably low at just 4.2 percent, suggesting that the vast majority of patients found the side effects manageable and outweighed by the cognitive benefits.[2]

For the psychiatric community, the arrival of a true triple-reuptake inhibitor represents a maturation of neuropharmacology. For decades, the field has relied on blunt instruments—drugs that flood the brain with a single neurotransmitter and leave clinicians to manage the collateral damage. Centanafadine represents a shift toward precision psychopharmacology, where molecules are engineered to address the complex, interconnected reality of neurodivergent brains.[4][5]

Otsuka and Lundbeck have confirmed they are preparing a New Drug Application (NDA) for submission to the FDA later this year. If the regulatory review proceeds without delays, centanafadine could be available to patients by the second half of 2027. The FDA's review will also trigger a crucial evaluation by the Drug Enforcement Administration (DEA), which will determine whether the drug's mild dopaminergic activity warrants scheduling as a controlled substance.[1][2]

Until then, the Phase 3 data stands as a beacon of hope for a deeply underserved patient population. The era of forcing adults to choose between treating their executive dysfunction and protecting their peace of mind appears to be drawing to a close. By successfully targeting the intersection of attention and anxiety, centanafadine is poised to rewrite the clinical guidelines for adult ADHD.[4][5]